Project Grant R01CA285967
Award Date
4/1/25
Completion Date
3/31/30
Dollars Obligated
$378K
Federal Agency
National Cancer Institute
Federal Grant Program
93.395
Assistance Type
Project Grant
Place of Performance
Indiana, USA
Similar Awards
The National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is providing a $639,790 Project Grant award to the H. Lee Moffitt Cancer Center and Research Institute Hospital, Inc. to support research investigating the role of chromatin remodeling and the histone variant H3.3 in regulating the dormancy and proliferation of metastatic breast cancer cells.
The key objectives of the 5-year project (Jul 2024 - Jun 2029) are to: 1) establish how HIRA-mediated H3.3 deposition into...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $619,279 to The University of Texas Southwestern Medical Center to conduct research aimed at uncovering the molecular determinants of metastatic recurrence and impaired natural killer (NK) cell function in HER2+ breast cancer.
The funded research employs innovative, unbiased approaches and novel preclinical models to elucidate how disseminated HER2+ breast cancer cells survive in the...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is focused on elucidating the mechanisms by which metastatic breast cancer cells facilitate breach of the blood-brain barrier (BBB) to enable brain metastasis. The $479,591 award, spanning March 2025 to February 2030, will be used by the University of Illinois to:
Investigate how glycosylation of the breast cancer-secreted protein fetuin-A (FETA) enables it to transiently open the...
This federal Project Grant award, totaling $719,799.00, was provided by the National Cancer Institute (NCI) under its Cancer Biology Research program (CFDA 93.396). The grant aims to investigate the impact of metabolic adaptations on the tumor microenvironment and immune response in metastatic triple-negative breast cancer (TNBC). Key objectives include:
Examining the bifunctional mechanisms by which the metabolic enzyme PFKFB4 regulates TNBC tumor cell plasticity and metastatic competence...
This Project Grant award from the National Cancer Institute's Cancer Biology Research program (CFDA 93.396) is funding a research project to investigate mechanisms of immune therapy resistance. The $620,820 award to The General Hospital Corporation (Massachusetts General Hospital) supports studies to: 1) understand the molecular regulation and transcriptional effects of the CREB5 transcription factor, which was identified as a driver of immune evasion; 2) examine CREB5-interacting proteins...
This $447,340 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research) aims to improve the survival rate of patients with metastatic, endocrine-resistant breast cancer. The primary objectives are to investigate epigenetic vulnerabilities and identify new therapeutic targets related to the CoREST-SWI/SNF axis in breast cancer cells with estrogen receptor (ER) mutations or SWI/SNF gene mutations. This 5-year research project, with a start date of March 1,...
This Project Grant, awarded by the National Cancer Institute (NCI) under the Cancer Research Manpower (CFDA 93.398) program, provides $208,415.00 in funding to Duke University to conduct research on the mechanisms of macrophage-mediated immune evasion in residual tumors. The research aims to investigate how residual cancer cells evade the immune system, specifically by upregulating "don't eat me" markers like CD47, following treatment with oncogene-targeted therapies. The project...
The National Cancer Institute (NCI), part of the National Institutes of Health (NIH), has awarded a $502,516 Project Grant under the Cancer Treatment Research program (CFDA 93.395) to Case Western Reserve University's Office of Research Administration. This 5-year grant, starting on April 1, 2025, aims to further investigate the impacts of newly developed small molecule degraders that target the nuclear-specific Heat Shock Transcription Factor 1 (HSF1) on leukemic stem cell self-renewal in...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), provides $701,408 to The General Hospital Corporation (Massachusetts General Hospital) to conduct research aimed at elucidating resistance mechanisms and enhancing response to immune checkpoint blockade in central nervous system (CNS) metastases from breast cancer. The project involves several ongoing Phase II clinical trials exploring the use of newly...
This $610,783 Project Grant award from the National Cancer Institute (CFDA 93.395 Cancer Treatment Research program) will support research at The Methodist Hospital Research Institute in Houston, Texas. The research aims to develop a novel gene delivery approach using a recombinant adenovirus to modulate the tumor microenvironment and enhance antigen-specific anti-tumor immunity, particularly for triple-negative breast cancer patients. The key products and services to be delivered...